

Journal Reading: HIV manifestations in Otolaryngology

Prasad et al. American Journal of Otolaryngology, 2006

Impact Factor: 1.7

Cite Score: 3.7

Citation: 136



Presenter Clerk2: 李祐全
Supervisor VS: 洪偉誠





Government Wenlock Hospital (Administrative Building)
 ಸರ್ವಕಾರಿ ನ್ಲಾಕ್ ಆಸ್ಪತ್ರೆ (ಆಡಳಿತದ ಕಛೇರಿ)
 3.0 ★★★★★ (33)
 醫院 · ॐ

總覽 評論 簡介

規劃路線 儲存 附近 傳送到手機 分享



Dr. Kishore Chandra Prasad

- Master of Surgery (MS)
- Fellow of the American College of Surgeons (FACS)




Study design and setting

Design	retrospective + prospective study
Center	Department of Otolaryngology–Head and Neck Surgery, Kasturba Medical College, Mangalore, South India
Period	Jan 1996 – Dec 2004 (9 years)
Sample size	968 HIV-positive patients
Main aim	Incidence, presentation, diagnostic tools, management, survival




Patient Recruitment and Workup

- **Two sources of patients:**
 - **ENT clinic and medical wards**
- **Workup**
 - **clinical history and ENT examination**
 - **Baseline laboratory tests**
 - **ELISA and Western blot**
 - **Further tests were selected according to lesion site**



Treatment strategy and follow-up

- ART regimen
 - 3-drug HAART-era regimen
 - stavudine / zidovudine / lamivudine
 - efavirenz / nevirapine based
 - older toxicity/tolerability profile
- Site-specific management






Clinical Distribution

Sex Ratio	3:1
most common age	31-40

Table 1. Presenting symptoms in our series

Symptoms	No. of patients	Percentage
Cough with expectoration	620	64
Weight loss	503	53
Fever	387	40
Generalized weakness	232	24
Oral and oropharyngeal complaints	474	49
Neck swelling	436	45
Nasal complaints	251	26
Ear complaints	193	20
GIT complaints	154	16
Dyspnea	39	4
Altered sensorium	39	4


Transmission Route






Main results: where do HIV patients show up in ENT?

Sex Ratio	3:1
most common age	31-40





Oropharyngeal Manifestation




**Candidiasis,
oral cavity
HIV (+)**



**Candidiasis,
hard palate
HIV (+)**




Neck Manifestation




**Cervical lymphadenopathy
HIV (+)**



Nasal and Otologic manifestations






Discussion: Clinical Interpretation

- **Oral/oropharyngeal disease was the dominant ENT presentation.**
- **Cervical lymphadenopathy should not be oversimplified.**
- **Sinonasal and otologic disease may become difficult to manage.**



Discussion: Clinical Interpretation

- **Oral/oropharyngeal disease was the dominant ENT presentation.**
 - **This is consistent with prior reports of oral lesions in HIV. (50%-80%, Williams., 1987, Deb et al., 2003).**
 - **Extension to the hypopharynx/larynx may cause severe odynophagia (Silverman et al., 1986).**
 - **Consider esophageal involvement if symptoms are extensive.**



Discussion: Clinical Interpretation

- **Cervical lymphadenopathy should not be oversimplified.**
 - **Neck involvement diverse from reactive lymphadenitis, tuberculous lymphadenitis, and lymphoma.**



Discussion: Clinical Interpretation


- **Cervical lymphadenopathy should not be oversimplified.**
 - **FNAC/ Biopsy should be considered when:**

1. marked constitutional symptoms with otherwise negative findings on evaluation;
2. adenopathy that is clearly asymmetric or nongeneralized;
3. a single disproportionately enlarging node in a patient with generalized adenopathy;
4. peripheral cytopenia with otherwise negative findings on evaluation;
5. other reasons for suspicion of a treatable pathological process.



- **Small-cleaved lymphoma**
- **Focal Kaposi's sarcoma**
- **Disseminated tuberculosis**
- **Histoplasmosis**

(Abrams et al., 1986)




Discussion: Clinical Interpretation

- **Sinonasal and otologic disease may become difficult to manage.**
 - **Progressive immunosuppression may lead to chronic or refractory disease.(Sample et al., 1990).**
 - **Persistent symptoms warrant culture and CT imaging.**
 - **FESS may be useful in selected sinonasal cases.**



Take-Home Message

- **Think HIV when common ENT complaints become recurrent, extensive, or atypical.**
- **The oral cavity/oropharynx is the most important site to recognize.**
- **Neck masses in HIV need structured differential diagnosis.**
- **Persistent sinonasal or otologic disease may require escalation of workup and management.**



Reference

- Prasad, H. K. C., Bhojwani, K. M., Shenoy, V., & Prasad, S. C. (2006). HIV manifestations in otolaryngology. *American journal of otolaryngology*, 27(3), 179-185.
- Williams, M. A. (1987). Head and neck findings in pediatric acquired immune deficiency syndrome. *The Laryngoscope*, 97(6), 713-716.
- Deb, T., Singh, N. B., Devi, H. P., & Sanasam, J. C. (2003). Head and neck manifestations of HIV infection: a preliminary study. *Journal of the Indian Medical Association*, 101(2), 93-95.
- Silverman Jr, S., Migliorati, C. A., Lozada-Nur, F., Greenspan, D., & Conant, M. A. (1986). Oral findings in people with or at high risk for AIDS: a study of 375 homosexual males. *The Journal of the American Dental Association*, 112(2), 187-192.
- Abrams, D. I. (1986). AIDS-related lymphadenopathy: the role of biopsy. *Journal of Clinical Oncology*, 4(2), 126-127.
- Sample, S., Chernoff, D. N., Lenahan, G. A., Serwonska, M. H., Rangi, S., Sherman, J. W., ... & Goetzl, E. J. (1990). Elevated serum concentrations of IgE antibodies to environmental antigens in HIV-seropositive male homosexuals. *Journal of allergy and clinical immunology*, 86(6), 876-880.

Thanks!

**Please applaud and
no hard questions**






Survival / mortality in this cohort

Table 4
Causes of mortality in our series

Mortality	No. of cases	Percentage
Death	112	11.5
Meningitis	40	4.1
Pulmonary TB	25	2.6
Pneumonia/wasting syndrome	24	2.4
HIV encephalopathy	15	1.5
Acute renal failure	2	0.2
Hepatic failure	2	0.2
Suicide	2	0.2

Interpret cautiously: pre-modern ART era, incomplete long-term follow-up



Early HAART-era regimen vs current ART

This paper (1996–2004)	Current practice
3-drug HAART-era regimen	Early ART for all patients
stavudine / zidovudine / lamivudine	TAF/TDF + FTC/3TC backbone
efavirenz / nevirapine based	INSTI-based, e.g. bictegravir or dolutegravir
older toxicity/tolerability profile	better tolerated, higher-barrier modern regimens